280 related articles for article (PubMed ID: 27535331)
21. Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.
Kittanakom S; Shajib MS; Garvie K; Turner J; Brooks D; Odeh S; Issenman R; Chetty VT; Macri J; Khan WI
Can J Gastroenterol Hepatol; 2017; 2017():1450970. PubMed ID: 28491862
[No Abstract] [Full Text] [Related]
22. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.
Kok L; Elias SG; Witteman BJ; Goedhard JG; Muris JW; Moons KG; de Wit NJ
Clin Chem; 2012 Jun; 58(6):989-98. PubMed ID: 22407858
[TBL] [Abstract][Full Text] [Related]
23. Selecting children with suspected inflammatory bowel disease for endoscopy with the calgranulin C or calprotectin stool test: protocol of the CACATU study.
Heida A; Van de Vijver E; Muller Kobold A; van Rheenen P
BMJ Open; 2017 May; 7(5):e015636. PubMed ID: 28554936
[TBL] [Abstract][Full Text] [Related]
24. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
25. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
[TBL] [Abstract][Full Text] [Related]
26. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.
Petryszyn P; Staniak A; Wolosianska A; Ekk-Cierniakowski P
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1306-1312. PubMed ID: 31464777
[TBL] [Abstract][Full Text] [Related]
27. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease.
Akobeng AK
Acta Paediatr; 2018 Nov; 107(11):2019-2023. PubMed ID: 29706011
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
29. Faecal calprotectin in children with chronic gastrointestinal symptoms.
Bremner A; Roked S; Robinson R; Phillips I; Beattie M
Acta Paediatr; 2005 Dec; 94(12):1855-8. PubMed ID: 16421055
[TBL] [Abstract][Full Text] [Related]
30. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
Roszak D; Gałęcka M; Cichy W; Szachta P
Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
[TBL] [Abstract][Full Text] [Related]
31. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study.
Hasler S; Zahnd N; Müller S; Vavricka S; Rogler G; Tandjung R; Rosemann T
BMJ Open; 2015 Mar; 5(3):e007306. PubMed ID: 25757949
[TBL] [Abstract][Full Text] [Related]
32. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
33. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
Saha A; Tighe MP; Batra A
Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
[TBL] [Abstract][Full Text] [Related]
34. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
[TBL] [Abstract][Full Text] [Related]
35. Guidance on the interpretation of faecal calprotectin levels in children.
Orfei M; Gasparetto M; Hensel KO; Zellweger F; Heuschkel RB; Zilbauer M
PLoS One; 2021; 16(2):e0246091. PubMed ID: 33571226
[TBL] [Abstract][Full Text] [Related]
36. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort.
Burri E; Manz M; Rothen C; Rossi L; Beglinger C; Lehmann FS
Clin Chim Acta; 2013 Feb; 416():41-7. PubMed ID: 23178549
[TBL] [Abstract][Full Text] [Related]
38. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
39. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.
van Rheenen PF; Van de Vijver E; Fidler V
BMJ; 2010 Jul; 341():c3369. PubMed ID: 20634346
[TBL] [Abstract][Full Text] [Related]
40. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders.
Lozoya Angulo ME; de Las Heras Gómez I; Martinez Villanueva M; Noguera Velasco JA; Avilés Plaza F
Gastroenterol Hepatol; 2017 Mar; 40(3):125-131. PubMed ID: 27260632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
